EU/3/22/2702: Orphan designation for the treatment of linear IgA bullous dermatosis

Human IgG4k monoclonal antibody against CD89

Table of contents


This medicine was designated as an orphan medicine for the treatment of linear IgA bullous dermatosis in the European Union on 11 October 2022.

This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the stage where they can apply for a marketing authorisation.

Orphan designation does not mean the medicine is available or authorised for use. All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.

During the medicine's development, doctors may be able to enrol patients in clinical trials investigating the medicine. For information on ongoing clinical trials in the EU, see:

Key facts

Active substance
Human IgG4k monoclonal antibody against CD89
Intended use
Treatment of linear IgA bullous dermatosis
Orphan designation status
EU designation number
Date of designation

Jjp Biologics Sp. z o.o.
Ul. Bobrowiecka 8
00-728 Warsaw

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating